用于构建最优生物标志物组合的变换判别分析
Transformation Discriminant Analysis for Constructing Optimal Biomarker Combinations
AI总结:
本文提出变换判别分析(TDA)框架,通过似然比函数组合多个生物标志物构建最优诊断评分,在保持参数化效率和小样本性能的同时兼顾分布灵活性,并在肝细胞癌诊断中验证了其有效性。
摘要:
准确的诊断检测对于有效的筛查和治疗至关重要。然而,单个生物标志物往往无法提供足够的诊断准确性,因为它们通常只能反映复杂疾病过程的一个方面。将多个生物标志物组合起来,每个标志物捕捉不同的机制,有助于构建信息更丰富的诊断检测。在实践中,逻辑回归被默认用于组合生物标志物,但当生物标志物分布呈现偏态或在疾病组之间存在差异时,其表现可能较差。非参数方法提供了更大的灵活性,但通常需要大样本量,而生物医学研究中样本量往往不足。我们提出了一个名为变换判别分析(transformation discriminant analysis)的新框架,该框架通过似然比函数组合生物标志物,以构建理论上最优的诊断评分。变换判别分析在灵活性与效率之间取得平衡。它能够适应广泛的分布形态和疾病特异性的相关结构,同时保持完全参数化。这使得可以进行似然推断,并且即使在小样本情况下也具有很强的性能。我们通过模拟评估TDA,并将其性能与常用方法进行基准比较。最后,我们展示了其在构建肝细胞癌最优诊断检测中的应用价值,肝细胞癌是一种没有单一理想生物标志物的疾病。我们提供了一个开源的R实现,以促进可重复性和更广泛的应用。
英文摘要:
Accurate diagnostic tests are essential for effective screening and treatment. However, individual biomarkers often fail to provide sufficient diagnostic accuracy, as they typically capture only one aspect of the complex disease process. Combining multiple biomarkers, each capturing a distinct mechanism, can help constructing more informative diagnostic tests. In practice, logistic regression is used as the default to combine biomarkers, but it can perform poorly when biomarker distributions exhibit skewness or differ across disease groups. Nonparametric methods provide more flexibility but generally require large sample sizes that are infrequently available in biomedical research. We propose a novel framework called transformation discriminant analysis which combines biomarkers through the likelihood ratio function to construct theoretically optimal diagnostic scores. Transformation discriminant analysis balances between flexibility and efficiency. It can accommodate a wide range of distributional shapes and disease-specific dependence structures while remaining fully parametric. This allows for likelihood inference and strong performance even in small-sample settings. We evaluate TDA through simulations and benchmark its performance against commonly used methods. Finally, we illustrate its utility in constructing an optimal diagnostic test for hepatocellular carcinoma, a disease with no single ideal biomarker. An open-source R implementation is provided for reproducibility and broader application.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。